Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 1.86MM shares of AnaptysBio Inc (ANAB). This represents 6.5% of the company.
In their previous filing dated February 3, 2022 they reported 1.87MM shares and 6.80% of the company, a decrease in shares of 0.48% and a decrease in total ownership of 0.30% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 31.65% Upside
As of January 31, 2023, the average one-year price target for AnaptysBio is $32.77. The forecasts range from a low of $23.23 to a high of $46.20. The average price target represents an increase of 31.65% from its latest reported closing price of $24.89.
The projected annual revenue for AnaptysBio is $15MM, an increase of 243.21%. The projected annual EPS is $-4.45.
Fund Sentiment
There are 294 funds or institutions reporting positions in AnaptysBio. This is a decrease of 48 owner(s) or 14.04%.
Average portfolio weight of all funds dedicated to US:ANAB is 0.1216%, an increase of 6.3522%. Total shares owned by institutions increased in the last three months by 2.01% to 33,506K shares.
What are large shareholders doing?
EcoR1 Capital holds 7,521,024 shares representing 26.45% ownership of the company. No change in the last quarter.
Tang Capital Management holds 2,628,678 shares representing 9.25% ownership of the company. No change in the last quarter.
Point72 Asset Management holds 2,526,200 shares representing 8.89% ownership of the company. In it's prior filing, the firm reported owning 851,800 shares, representing an increase of 66.28%. The firm increased its portfolio allocation in ANAB by 252.80% over the last quarter.
Federated Hermes holds 2,372,923 shares representing 8.35% ownership of the company. In it's prior filing, the firm reported owning 2,304,097 shares, representing an increase of 2.90%. The firm increased its portfolio allocation in ANAB by 39.40% over the last quarter.
Deerfield Management Company, L.p. holds 1,466,600 shares representing 5.16% ownership of the company. In it's prior filing, the firm reported owning 772,000 shares, representing an increase of 47.36%. The firm increased its portfolio allocation in ANAB by 130.39% over the last quarter.
AnaptysBio Background Information
(This description is provided by the company.)
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
